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Abstract We have found that the gene expression of the ninth 
member of the fibroblast growth factor (FGF) family, FGF9 was 
induced during retinoic acid(RA)-induced neuronal differentia- 
tion of murine embryonal carcinoma P19 ceils. We have reported 
here the nucleotide sequence of the mouse FGF9 cDNA. The 
murine cDNA showed 92.4% nucleotide sequence homology to 
the human FGF9 cDNA and 98.2% homology to that of rats. This 
mouse FGF9 cDNA encoded a polypeptide consisting of 208 
amino acids with amino acid sequence identical to that of rats. 
Only one amino acid was replaced compared to the human ho- 
molog. The highly conserved sequence homology of FGF9 sug- 
gests its functional importance. FGF9 was originally isolated 
from a culture medium of a human glioma cell line as a growth- 
promoting factor for glial cells [5]. Upon induction of neuronal 
differentiation by forming cell aggregates with 10 -6 M RA, the 
gene expression of FGF9 was increased biphasically during the 
first 96 hours when cells were aggregating and from 168 hours 
to 192 hours followed by plating onto a tissue culture dish as 
gila-like cells proliferated. Neither undifferentiated P19 cells nor 
the cells aggregated without RA remaining undifferentiated ex- 
pressed FGF9. This indicates that RA regulates the gene expres- 
sion of FGF9 that may play an important role in neuronal differ- 
entiation in both early and late developmental process. 
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1. Introduction 
Mouse P19 embryonal carcinoma (EC) cells are pluripotent 
and can be induced to differentiate into different cell types with 
forming cell aggregates and upon treatment with varying con- 
centrations of retinoic acid(RA) [7]. The differentiated cell 
types are dependent on the concentration of RA. P19 cells 
exposed to lower concentrations of RA (10 -8 M to 10 -9 M) are 
characterized by an abundance of cardiac muscle cells and 
skeletal muscle cells, while neurons and astroglia appear at 
higher concentrations (10 -7 M to 10 -6 M) of RA [7]. These 
neurons resemble morphologically those in the central nervous 
system, and many neuron-specific genes were shown to be ex- 
pressed in those cells [8]. RA is now believed to play a funda- 
mental role in the development of the vertebrate nervous ys- 
tem [19,20]. Thus, P19 EC cells are a good model system for 
studying what events occur during the critical phase of neu- 
ronal differentiation i  vitro. 
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Members of the fibroblast growth factor (FGF) family are 
involved in cell proliferation processes, but also in early and 
late differentiation processes for a variety of mesoderm- and 
neuroectoderm-derived cells[1]. Among the nine members of 
this group identified to date, FGF1/acidic FGF and FGF2/ 
basic FGF are expressed inboth embryonic and in adult issues 
[2], but are most abundant in nervous tissues [2]. FGF1 and 
FGF2 have neurotrophic activities which support he survival 
and growth of cultured peripheral neurons, central neurons and 
glial cells [1]. On the other hand, other FGF family members, 
such as FGF3/int-2, FGF4/hst-1, FGF5, and FGF6, have been 
initially identified, as products of oncogenes, being shown to 
play roles during murine embryonic development [3]. In addi- 
tion, FGF5 has been found in brains of adult mouse and rat 
and promotes differentiation f cultured rat septal cholinergic 
and raphe serotonergic neurons [16]. FGF8 and FGF9 have 
recently been found and purified from the culture media of a 
mouse androgen-dependent mammary carcinoma cell line [4] 
and a human glioblastoma cell line [5], respectively. FGF8 has 
been suggested to play a role in mouse embryogenesis [17]. 
However, the role of FGF9 in cell differentiation a d develop- 
mental process has not been investigated yet. These FGFs bind 
to cell-surface receptors to give target cells signals determining 
their fate to proliferate, survive, or differentiate. As such recep- 
tors, four members of the FGF receptor (FGFR) family, of 
which the cytoplasmic domains are tyrosine kinases, have been 
identified [14]. Thus, FGFs and FGFRs may regulate not only 
mesoderm induction but neuronal induction during both early 
and late developments, although less information is available 
on the expression pattern in the nervous ystem of members of 
the FGF family different from FGF1 or FGF2. 
In this study, we have found that the gene expression of the 
ninth member of the FGF family, FGF9, was induced uring 
retinoic acid-induced neural differentiation i P19 cells. We 
cloned and sequenced mouse FGF9 cDNA expressed in the 
cells induced by RA. 
2. Materials and methods 
2.1. Cell culture and differentiation fP19 cells 
EC P19 cells were cultured as described previously [9]. Briefly, the 
cells were seeded at a density of 105 cells/rnl in s-minimal essential 
medium (~-MEM) containing 10% fetal bovine serum, and incubated 
at 37°C in a humidified atmosphere containing 5% CO2 and passaged 
every second ay. The cells were dispersed with 0.05% trypsin and0.53 
mM EDTA and seeded at a density of 10 s ceUs/ml in ~-MEM contain- 
ing 10% fetal bovine serum with or without 10 -6 M RA (all-trans; 
Sigma) in 100 mm bacteriological dishes. After 48 hours, the aggregates 
were resuspended in a fresh medium. After a total of 96 hours in 
suspension culture, the aggregates were collected and treated with tryp- 
sin-EDTA. The cells were counted and transferred into 100 mm tissue 
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culture dishes at a density of 2 x 105 cells/ml in fresh medium without 
RA. The medium was changed every second day. 
2.2. RNA isolation and gel electrophoresis 
At various time intervals, total cellular RNA was isolated with the 
guanidium thiocyanate extraction method [10]. The amount of total 
RNA was checked by electrophoresis in 1% agarose gels containing 
2.2 M formaldehyde and 0.5 gg/ml ethidium bromide. 
2.3. Reverse transcription 
First strand cDNA was synthesized using MMLV reverse transcrip- 
tase (First strand cDNA synthesis kit, Pharmacia). The RNA (5 #g in 
8 ~tl) was heated at 65°C for 10 min and then cooled on ice. Then, 11 
/A of first strand cDNA synthesis reaction mixture (135 mM Tris-HC1, 
pH8.3, 204 mM KC1, 27 mM MgC12, 5.4 mM each dNTP, 0.24 mg/ml 
BSA), 1/11 of 0.2 M dithiothreitol, and 1 #1 of either NotI d(T)~8 primer 
(0.2/.tg) or random d(N)6 primer (0.2/tg) were added to the RNA 
solution. After incubation at 37°C for 1 h the mixture was heated to 
95°C for 5 min, chilled on ice and stored at -20°C. 
2.4. Polymerase chain reaction (PCR) amplification 
PCR was performed in a reaction mixture of 50/11, 5.0/11 of a cDNA 
synthesis reaction mixture (from tenfold dilutions to one thousand 
dilutions), 50 mM KC1, 10 mM Tris-HC1, pH 9.0 at 25°C, 1.5 mM 
MgC12, 0.1% Triton X-100, 200 #M in each dNTP, 1.25 units of Taq 
polyrnerase (Pharmacia), 25 pmol each of forward and reverse se- 
quence-specific primers for 30 cycles of 1 min at 94°C, 2 min at 55°C, 
3 min at 72°C, with an extra 7 rain final extension at 72°C for the last 
cycle. Aliquots of PCR products (10 #1) were electrophoresed in 3.5% 
agarose gels (Nusieve GTG/Seakem) in Tris-acetate-EDTA buffer, pH 
8.0, and stained with 0.5 gtg/ml ethidium bromide. Linear amplification 
dependent on the amount of RNA was obtained under the above 
conditions (from 1.7 to 170 ng RNA). The amounts of mRNA were 
adjusted in each RT-PCR reaction by checking amplification of the 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) transcript. 
The forward and reverse primers used for analysis of FGF9 and 
GAPDH gene expression are summarized in Table 1. 
2.5. Sequence ofthe mouse FGb x) cDNA 
The DNA amplified using the forward primer (5'-GAGTTGGAT- 
ATACCTCGCCT) and the reverse primer (5'-AAGAACCCACCGC- 
ATGAAGC) was extracted with phenol/chloroform and precipitated 
with ethanol. Then, the DNA was ligated into pT7 Blue vector 
(Novagen). Cells of competent E. eoli (Nova Blue) were transformed 
with the ligated vector. The plasmids of positive clones were extracted 
and the nucleotide sequences of their inserts were determined in both 
orientations with a BcaBest dideoxy sequencing kit (Takara) using 
[~-33p]dCTE 
3. Results 
3.1. RA-induced iJferentiation of EC P19 cells 
Fig. 1 shows the morphologies of  the cell types found in both 
RA-treated and non-treated cultures of EC P19 cells. When 
undifferentiated cells (as shown in Fig. IA) were dispersed with 
trypsin and plated into bacteriological dishes with or without 
10 -6 M RA, cells aggregated spontaneously (Fig. 1B, C). After 
96 h of incubation in aggregated state and plating in tissue 
culture dishes, the cells were induced to differentiate to neurons 
and glia-like cells, as described previously by Edwards and 
McBurney [7,9]. 144 h from the beginning of the incubation, 
neurons extended their neurites onto glia-like cells (Fig. 1D). 
After an additional 24 h of incubation, the number of glia-like 
cells increased (Fig. IF). On the other hand, when cells were 
Table 1 
Sequences and positions of oligonucleotides u ed as primers in RT- 
PCR 
Target Oligonucleotide s quence Locus (region 
cDNA of cDNA am- 
plified) 
FGF9 F 5'-TTAAAGGGGATTCTCAGGCG MFGF9 
R 5'-AAGAACCCACCGCATGAAGC (346-872) 
GAPDH F 5'-ACCACAGTCCATGCCATCAC G3PDH* 
R 5'-TCCACCACCCTGTTGCTGTA (58(~1037) 
Sequences of the forward (F) and reverse (R) primers, and the Locus 
(GenBank) of the cDNA amplified are summarized. *The primers for 
glyceraldehyde 3-phosphate d hydrogenase w re purchased from Clon- 
tech, Inc. 
aggregated but not exposed to RA, the morphology of the cells 
appeared undifferentiated after 144 h of incubation (Fig. 1E). 
After an additional 24 h of incubation, many of these undiffer- 
entiated cells became super-confluent but not differentiated 
(Fig. 1G). 
3.2. RA-induced expression of FGF9 mRNA in EC P19 cells 
To determine the changes in levels of gene expression of 
FGF9 during the induction of neuronal differentiation of P19 
cells by 10 -6 M RA, we employed RT-PCR analysis with prim- 
ers for the rat FGF9 (Table I). The amounts of  mRNA were 
checked by performing RT-PCR using GAPDH primers (Table 
1). The specificity of  each RT-PCR reaction was verified by 
restriction analysis and sequencing of the PCR products. 
In the undifferentiated P 19 cells (at 0 h of  incubation), FGF9 
transcripts were not detected (Fig. 2). In the RA-treated cells, 
the gene expression of FGF9 was stimulated in the aggregates 
from 8 h to 48 hr and from 168 hr to 192 hr as the number of 
glia-like cells increased and neurons extended an increasing 
number of neurites onto glia-like cells (Fig. 2 +RA). On the 
other hand, the gene expression of FGF9 was not stimulated 
in the cells aggregated but not treated with RA (Fig. 2 -RA) .  
3.3. Sequence of the mouse FGF9 cDNA 
The sequence of the mouse FGF9 cDNA is reported here for 
the first time (Fig. 3). The forward and reverse primer for 
amplification of mouse FGF9 cDNA were based on the human 
and rat FGF9 cDNA sequences [5]. The murine cDNA showed 
92.4% nucleotide sequence homology to the human FGF9 
cDNA and 98.2% homology to that of rats. This mouse FGF9 
cDNA encoded a polypeptide consisting of 208 amino acids 
with amino acid sequence identical to that of rats. The ninth 
amino acid from the N-terminus in the mouse FGF9 was serine 
being replaced by asparagine in the human homolog. Sequence 
similarity to other members of  the FGF  family was estimated 
to be around 30%. 
4. Discussion 
We have analyzed the mouse FGF9 cDNA nucleotide se- 
quence as expressed in RA-treated P19 cells and showed its 
Fig. 1. Phase-contrast photomicroraphs of P19 EC cells. (A) Undifferentiated P19 cells growing on a tissue culture dish. (B) P19 cell aggregates treated 
with 10 -6 M RA after 72 h of incubation on a bacteriological dish. (C) P19 cell aggregates without RA after 72 h on bacteriological dishes. (D,F) 
Differentiated cells plated in a tissue culture dish without RA following aggregation for 96 h and exposure to 10 -6 M RA. Neurons and glial cells 
appeared at 144 h (D) or at 168 h (F) from the beginning of the experiments. (E,G) Cells remained undifferentiated at 144 h (E) or at 168 h (G) following 
plating on tissue culture dishes as described in (C). (Magnification: A, D, E, F, G, × 170, B, C, × 34.) 
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Fig. 2. Expression of FGF9 mRNA in P19 EC cells. Total RNA of P19 cells aggregated in the absence (-RA) or in the presence of 10 -6 M RA (+RA) 
and plated onto tissue culture dishes as described in section 2, were analyzed. The RT reaction mixtures containing cDNA were diluted with distilled 
water, and then 5/.tl of the diluted cDNA was used for PCR. The PCR primers for FGF9 and GAPDH are shown in Table 1. The PCR products 
were electrophoresed in 3.5% agarose gels (Nusieve Siekam) and stained with ethidium bromide. 
highly homologous sequence to the FGF9 of humans and rats. 
The expression of FGF9 correlates with the time when the 
number of glial cells increases and neurons extends their 
neurites in tissue culture dishes, while cells aggregated in the 
absence of RA remained undifferentiatied and did not express 
FGF9. This suggests its functional importance not only as a 
glial cell growth stimulating factor, but also as a cue for neurons 
to extend their neurites onto glial cells. FGF9 may have the 
characteristics to bind to extracellular p oteoglycans following 
secretion, as FGF 1 and FGF2 [3], because FGF9 was originally 
isolated from a culture medium of a human glioma cell line as 
a growth-promoting factor for glial cells, using heparin affinity 
chromatography [5]. Although it has been reported that FGF9 
lacks a typical N-terminal signal sequence for secretion, it is 
constitutively secreted following transfection i to COS cells [6]. 
In an early stage of neural tube development, FGF2 has been 
reported to be involved in the developmental regulation of 
adhesive interaction between euroepithelial cells and the ex- 
tracellular matrix, thereby controlling their proliferation, mi- 
gration and differentiation [12]. Thus, FGF9 may play a role 
in not only stimulating proliferation of glia cells but supporting 
neurons to differentiate, extend their neurites, and connect 
neurites and target cell junctions. It remains to be determined 
if the differentiated neurons or gila-like ceils express FGF9. 
FGF9 may play a role not only in the late developmental 
process as described above, but in the early developmental 
process when the cell fate was determined, because gene expres- 
sion of FGF9 was induced uring the first 48 hours forming cell 
aggregates with 10 -6 M RA. FGF9 was found to be secreted 
from cells after synthesis despite its lack of a typical signal 
sequence [6]. Thus, it is possible that secreted FGFs such as 
FGF9 may be the physiological ligands for FGFRs during early 
nervous ystem development [15]. While both FGF1 and FGF2 
were lacking typical signal sequence and primarily cell-as- 
sociated proteins, they were expressed during critical 
phases of development and high in the adult central nervous 
system [15]. 
It is also important o know which FGF  receptors accept 
FGF9 as a ligand and transfer the intracellular signals to pro- 
liferate or differentiate. Among four members of the FGF  re- 
ceptor family, each member has a different ligand specificity 
and affinity with some overlapping ligand specificities [14]. 
They also have different signaling transduction and biological 
response induction capabilities [18]. In P19 EC cells, FGFR1, 
R2, and R3 mRNAs were expressed, and all were upregulated 
after differentiation to derivatives resembling parietal endo- 
derm [11]. FGFR1 and FGFR2 mRNAs were expressed by 
neurons and oligodendrocytes in the adult central nervous ys- 
tem, respectively [13]. Thus, more detailed analysis of which 
FGFRs are expressed in each neuronal or glial precursor cell 
and to which FGFRs FGF9 binds to promote their differenti- 
ation remains to be made. 
We do not know whether the RA receptor itself directly 
regulates gene expression of FGF9. Three different RA recep- 
tors (RAR-~, fl and 7/) has been shown to exist in human and 
mouse. Each RA receptor may play a specific role in RA- 
triggered cascades of transcriptional regulation of gene expres- 
sion in development. I  has been reported that two isoforms of 
mouse RA receptor-fl are not only preferentially expressed in 
both adult and fetal brain, but also up-regulated in RA-treated 
P19 ceils [21]. It suggests that they play a specific role in the 
central nervous system. We are now analyzing the molecular 
mechanisms by which RA regulates the gene expression of 
FGF9. Furthermore, it is important to search for the factor(s) 
that controls the molecular switch to start the differentiation 
cascade for neuronal differentiation i vivo. 
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RAT 
HUMAN 
MOUSE 
RAT 
HUMAN 
MOUSE 
RAT 
HUMAN 
MOUSE 
RAT 
1 : TTATTCTTGTGAT-TAAA GCCGAGTCCTCTGATGGCTCCCTTAGGTGAA 
i: ", - ' ' , ° ' * , ,C 'CC °° ' ' "  ' ' ' ' "  ° ' ' ' ' ' ' ' ' "  ' ' ' ' ' ' ' "  ~ ' ° ' ' ' "  
I :  , ,  °o , ,e , , , °C , - , , ° , *  • ° t , ,  ° ,  , , , , °o* ,  °° , , ,  ,°  °° , , °  o** ,  
M A P L G E 
49 : GTTGGGAGCTATTTCGGTGTGCAGGACGCGGTACCGTTCGGGAACGTACC 
50: , , , ,  • , ,A° ,, .,, • ,,, • , , , ,  ° ° ,T , * , ° , , ,  -° o,T,  • ,o ,T° oG,,  
49: ° , , , . ° . , . - . . , . - . . , . - - , , . . , . . , , . . , ' , . - ° ° , °°° , , ' . ° . °  
: V G ~- ]Y  F G V Q D A V P F G N V P 
W 
99 : GGTGTTGCCGGTGGACAGTCCC.GTGTTGCTAAGTGACCACCTGGGTCAGT 
HUMAN i00:  C , , , , , , , , , oo , , , , , ,Co , , , ,T , , ,T , , , - , , , , , , o , , * ,  - . , , , .  
MOUSE 99: " - , * ' , , , - , . ' ' o , ' ' o ,o* , ' ' ' , ' ' ' °o ' ' ' ' ' ' ' * * ' ' , ' ' ' ' o ' '  
V L P V D S P V L L S D H L G Q S  
RAT 149:CCG~AGGGGGGCTGCCCCGGGGACCC~AGT~C~AC~A~AT 
HUMAN 150:  - - , , . . , . - . , - .o , ,C . . .A . . . , , . - . - , , - . - . ' , , . . ° . , ' ' . . . "  
MOUSE 149:  " . , , ° . , - -oo ' °° , * ' - ° ° ' * ' ° ' ' ' ' o , ,o ' ' ' ' ° ' ' ' ' ' o , ' *o ' ' "  
E A G G L P R G P A V T D L D H  
RAT 199:  ~AAAGGGGA~CAGCCGGAGGCA~T~ACTGCA~AC~GAT~ 
HUMAN 200:  " , . . . , , . . . o ' ' . . . ' * * . . . . ' * . . . 'A , . - , . ' ' , . . . , , , ' ' - , 'Q  
MOUSE 199:  ' , . ' ' . , , ' , . ' ' . ' ' ' , . , ' , ' ' ' . ° ' ' , , . , ' ' ' ' , . . ' , . , ' ' - ' ' '  
L K G I L R R R Q L Y C R T G F H  
RAT 249:CTTAGAAATC~CCCC~CGGTACTA~CAOGG~CCA~AAAGACCACA 
HUMAN 250:  " - . . ' , . . . o , ' ' - . . * .T . . - , * ' . , . . . , . - . - , ' , - , . , . , '~ . . . .  
MOUSE 249:  T* . , ° ,G*° . , ° . , . , , ° . - , . . , . , , . . . . , o , - . - , . , ° , - . ° ,o° ,~ 
L E I F P N G T I Q G T R K D H S  
RAT 299: ~CGA~CGGCA~CTGGAA~TA~A~ATA~AGTC-G~CTGGTCA~ 
HUMAN 300:  - . . , - . .T . .  . . . .  * . . . . . . . . . . . . . . . . . . . .  • . . . . . . . . . . . . . .  
MOUSE 299:  . . . .C . . - * . - - - . , . - . , , , . , . . , , , , . . . * . , , . . , , . , . , - , , , , ,  
R F G I L E F I S I A V G L V S  
RAT 349:AT~GTGGTGTGGACAGTGGAC~TACCTCGGCA~CGAGAAGGGGGA 
HUMAN 350:  , - - . ,A - ,C , .  . . . . .  • . . . .  ,, . . . . .  . , . .G , * , , .T . . , , , . , . - , ,  
MOUSE 349:  * . , , ,C , , , , , , o - , , , , , , , , , , , o - , , , , - ° , , , , , ° , , , , ° , , , , , ,  
I R G V D S G L Y L G M N E K G E  
RAT 399: ~TAT~A~AGAAAAACT~CACA~AG~CGTG~CAGAG~CAGT 
HUMAN 400:  . , , .6o , . , , . . ° . . , . , . , , , , oCo ,A , .o . ,T , ,Aooo , , , , ° .o , , ,  
MOUSE 399:  , , , - . . , , * . - - ° . . . ° , , ,~ . . . . , . . . .A . ,T . . . . , , , . . . . . * . . .  
L Y G S E K L T Q E C V F R E Q F  
RAT 449:  ~G~GAAAA~TAC~CAC~AC~CC~CC~TAC~ACG~ 
HUMAN 450:  ,C , , , . ° ,~* . . , ° ° ,T -oT° -G .°oo .G .°A°o , - .A . .T . , . ° . .o . .  
MOUSE 449:  , -o , , , °G , , ° . , ° ° , , . . ° .o , , ° - ° . . , , - , , , * ,C ,oT , ,A , ,T - , ,  
E E N W Y N T Y S S N L Y K H V  
RAT 499:GACACC~AGATACTA~A~AAAT~GGATGGGAC~C~G 
HUMAN 500: , , . . , T . . , - . .C . - . . . . . .  . . . .  ., . . . . .  , . .A  . . . .  . . . .C . .G , ,  
MOUSE 499:  - , , , , , , . , , , , , , , , , , ° . , . , , , . , , , , , , , , , , , ,C . . , . , * , * . . ,  
D T G R R Y Y V A L N K D G T P R  
RAT 549:AG~C-GGACCAG~AAACGGCACCAGAAAr i 'TTACA~ACCTA 
HUMAN 550:  , , . . , . . , , T . . , . . . , . . , , , . . . , . . , . . . ,C . . . . . . , * . . . . . , . ,  
MOUSE 549:  ,, . . . . .  , . . , ,  . . . .  * . . . . . . .  • . . . . . . . . .  • . . . . . . . . . . . . . . .  
E G T R T K R H Q E F T H F L P R  
RAT 599:GACCAGT~ACCCTGACAAAGTACCTG~ATAT~ATATTCT~ 
HUMAN 600: , , , , , . . ° . . , , .C , , . - . - , - . . , . . , . . .G . . . . . . . . . . . . - - . . . .  
MOUSE 599: . , ° , * °o -oo , - . , ° - , . . . , , . * . . , ,~° , ,~o .o° , * , . ° . , ° ° , , , ,  
P V D P D K V P E L Y K D I L S  
RAT 649:CAAAG~GACAAAGA~GTG~CACTT~CCTTAAAACA-T~CCA 
HUMAN 650:  , ° , . . ° ,o , * - , , ° ° , ,A .T , . . . . . , . , , . . * .o . ° , - - -A .G . .o . . .  
MOUSE 649:  , , , * ,C , . , , , ° , , , , , , , , , , , , , , , , , , , , * - ° , , , , , , o , - , , , , , °  
Q S X  
Fig. 3. Sequence of mouse FGF9 cDNA. Di~rences in the nucleotide 
and deduced amino acid sequences of the human, rat (5) and mouse 
FGF9 cDNAs are indicated by closed circles and boxed amino acid 
residues;rat, human, mouse, serine, aspargine, serine, respectively. The 
nucleotide sequence data reported in this paper will appear in the 
GSDG, DDBJ, EMBL, and NCBI nucleotide sequence databases with 
the ~llowing accession umber D38258. 
manuscript, and to Dr. Toru Terachi for technical advice, and to Dr. 
A. Wanaka for the kind gift of EC P19 cells. We would also like to 
thank Koichiro Tada and Yoshiharu Hayashi for participating in part 
of the experiments. This work was supported by a grant from the 
Ministry of Education, Science and Culture of Japan. 
References 
[1] Sensenbrenner, M. (1993) Progress in Neurobiology 41,683-704. 
[2] Gospodarowicz, D., Cheng, J., Lui, G., Baird, A. and Bohlen, P. 
(1984) Proc. Natl. Acad. Sci. USA 81, 6963-6967. 
[3] Baird, A. and Klagsbrun, M. (Eds.) (1991) Ann. N.Y. Acad. Sci., 
The Fibroblast Growth Factor Family, Volume 638, New York, 
New York Academy of Science. 
[4] Tanaka, A., Miyarnoto, K., Minamino, N., Takeda, M., Sato, B., 
Matsuo, H. and Matsumoto, K. (1992) Proc. Natl. Acad. Sci. USA 
89, 8928-8932. 
[5] Naruo K., Seko, C., Kuroshima, K., Matsutani, E., Sasada, R., 
Kondo,T. and Kurokawa, T (1993) J. Biol. Chem. 268, 2857-2864. 
[6] Miyamoto, M., Naruo, K., Seko, C., Mastumoto, S., Kondo, T. 
and Kurokawa, T. (1993) Mol. Cell. Biol. 13, 42514259. 
[7] Edwards, M.K.S. and McBurney, M.W. (1983) Dev. Biol. 98, 
187-191. 
[8] Ray, W.J. and Gottlieb, D.I. (1993) Biochem. Biophys. Res. Com- 
mun. 197, 1475-1482. 
[9] Rudnicki, M.A. and McBurney, M.W. (1987) in: Teratocarcino- 
mas and Embryonic Stem Cells, (E.J. Robertson, Ed.) pp. 1949. 
IRL Press, Oxford, Washington, DC. 
[10] Chomczynski, P.and Sacchi, N. (1987) Anal. Biochem. 162, 156- 
159. 
[11] Mummery, C.L, van Rooyen, M., Bracke, M., van den Eijinden- 
van Raaij, van Zoelen, E.J. and Alitalo, K. (1993) Biochem. Bio- 
phys. Res. Commun. 191, 188-195. 
[12] Kinoshita, Y., Kinoshita, C., Heuer, J.G. and Bothwell, M. (1993) 
Development 119, 943-956. 
[13] Asai, T., Wanaka, A., Kato, H., Masana, Y., Seo, M. and 
Tohyama, M. (1993) Mol. Brain Res. 17, 174-178. 
[14] Johnson, D.E. and Williams, L.T. (1993) Adv. Cancer Res. 60, 
141. 
[15] Eckenstein, F.P. (1994) J. Neurobiol. 25, 1467-1480. 
[16] Lindholm, D., Hartikka, J., Berzaghi, M. da P., Castren, E., 
Tzimagiorgis, G., Hughes, R.A. and Thoenen, H. (1993) Eur. J. 
Neurosci. 6, 244-252. 
[17] Ohuchi, H., Yoshioka, H., Tanaka, A., Kawakami, Y., Nohno, T. 
and Noji, S. (1994) Biochem. Biophys. Res. Commun. 204, 882- 
888. 
[18] Wang, J-K., Gao, G. and Goldfarb, M. (1994) Mol. Cell. Biol. 14, 
181-188. 
[19] Durston, A.J., Timmermans, J.P.M., Hage, W.H., Hendriks, H.F. 
H., de Vries, N.I-I., Heideveld, M. and Niewkoop, P.D. (1989) 
Nature 340, 140~144. 
[20] Wagner, M., Thaller, C., Jessell, T. and Eichele, G. (1990) Nature 
345, 819-822. 
[21] Zelent, A., Mendelsohn, C., Kastner, P., Krust, A., Gamier, J.-M., 
Ruffenach, F., Leroy, P. and Chambon, P. (1991) EMBO J. 10, 
71-81. 
